Skip to main content
. 2014 Feb 20;18(1):205. doi: 10.1186/cc13737

Table 3.

Potential benefits of glucagon-like peptide-1 based therapies in the critically ill

Potential benefit
Negligible risk of severe hypoglycaemia
Reduction in insulin requirement
Cardiovascular protection
Attenuated glycaemic variability
Amenable to continuous infusion without dose titration
Decreased blood glucose testing
Simplified protocol for medical and nursing staff